229975-97-7 | Atazanavir Sulfate

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$15.00	$10.00
50mg	98%	in stock	$18.00	$12.00
250mg	98%	in stock	$29.00	$20.00
1g	98%	in stock	$78.00	$54.00
5g	98%	in stock	$145.00	$101.00
25g	98%	in stock	$463.00	$324.00

Description

• Catalog Number: AF28040
• Chemical Name: Atazanavir Sulfate
• CAS Number: 229975-97-7
• Molecular Formula: C38H54N6O11S
• Molecular Weight: 802.934
• MDL Number: MFCD08067748
• SMILES: OS(=O)(=O)O.COC(=O)N[C@@H](C(C)(C)C)C(=O)NN(Cc1ccc(cc1)c1ccccn1)C[C@@H]([C@H](Cc1ccccc1)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O

Computed Properties

• Complexity: 1190
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 4
• Heavy Atom Count: 56
• Hydrogen Bond Acceptor Count: 13
• Hydrogen Bond Donor Count: 7
• Rotatable Bond Count: 18

Literature

• GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.

  Antimicrobial agents and chemotherapy 20131201

• GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.

  Antimicrobial agents and chemotherapy 20130501

• Effect of HIV protease inhibitors on New World Leishmania.

  Parasitology international 20121201

• Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.

  AIDS (London, England) 20121113

• Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

  Clinical pharmacology and therapeutics 20121101

• Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature.

  Expert opinion on pharmacotherapy 20121101

• The protease inhibitor atazanavir triggers autophagy and mitophagy in human preadipocytes.

  AIDS (London, England) 20121023

• Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.

  AIDS research and human retroviruses 20121001

• A population pharmacokinetic-pharmacogenetic analysis of atazanavir.

  AIDS research and human retroviruses 20121001

• Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.

  AIDS research and human retroviruses 20120901

• Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.

  The Journal of antimicrobial chemotherapy 20120901

• Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.

  Scandinavian journal of infectious diseases 20120901

• Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.

  British journal of clinical pharmacology 20120801

• Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20120801

• Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.

  The Journal of antimicrobial chemotherapy 20120801

• Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors.

  Virus research 20120801

• [A single tablet against HIV: new combination preparation improves therapy].

  Deutsche medizinische Wochenschrift (1946) 20120801

• Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users.

  AIDS (London, England) 20120731

• Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.

  AIDS (London, England) 20120717

• Monotherapy with atazanavir as a simplification strategy: results from an observational study.

  Journal of acquired immune deficiency syndromes (1999) 20120701

• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

  Lancet (London, England) 20120630

• Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.

  Drugs 20120618

• The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20120601

• Monitoring the risk of birth defects associated with atazanavir exposure in pregnancy.

  AIDS patient care and STDs 20120601

• A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.

  Journal of acquired immune deficiency syndromes (1999) 20120601

• Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.

  AIDS patient care and STDs 20120501

• Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient.

  Fundamental & clinical pharmacology 20120401

• Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.

  AIDS research and human retroviruses 20120401

• Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.

  HIV medicine 20120401

• Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.

  Pharmaceutical research 20120401

• Atazanavir: in pediatric patients with HIV-1 infection.

  Paediatric drugs 20120401

• The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.

  The Journal of antimicrobial chemotherapy 20120401

• Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.

  Therapeutic drug monitoring 20120401

• Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.

  AIDS (London, England) 20120313

• Comparison of extraction procedures for assessment of matrix effect for selective and reliable determination of atazanavir in human plasma by LC-ESI-MS/MS.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120215

• Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.

  Journal of acquired immune deficiency syndromes (1999) 20120201

• Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.

  The Journal of antimicrobial chemotherapy 20120201

• Severe atazanavir-associated hyperbilirubinemia revealing Canton G6PD deficiency in an Asian HIV-infected patient.

  AIDS (London, England) 20120114

• In vivo enhancement in bioavailability of atazanavir in the presence of proton-pump inhibitors using mesoporous materials.

  ChemMedChem 20120102

• HIV type 1 viral encephalitis after development of viral resistance to plasma suppressive antiretroviral therapy.

  AIDS research and human retroviruses 20120101

• A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.

  Journal of acquired immune deficiency syndromes (1999) 20120101

• Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

  The Lancet. Infectious diseases 20120101

• Unexpected atazanavir-associated biliary lithiasis in an HIV-infected patient.

  The Journal of antimicrobial chemotherapy 20120101

• Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.

  Antiviral therapy 20120101

• Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.

  Antiviral therapy 20120101

• Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.

  PloS one 20120101

• HIV-associated gastric natural killer/T-cell lymphoma.

  International journal of STD & AIDS 20120101

• Immune reconstitution renal-limited sarcoidosis presenting as acute kidney injury.

  International journal of STD & AIDS 20120101

• A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.

  Antiviral therapy 20120101

• Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.

  Journal of medical economics 20120101

• Interactions between phytochemical components of Sutherlandia frutescens and the antiretroviral, atazanavir in vitro: implications for absorption and metabolism.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20120101

• A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.

  HIV clinical trials 20120101

• Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.

  International journal of nanomedicine 20120101

• Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population.

  BMC infectious diseases 20120101

• Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.

  British journal of clinical pharmacology 20111201

• Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy.

  The AAPS journal 20111201

• Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.

  Journal of pharmacokinetics and pharmacodynamics 20111201

• HIV protease inhibitors induce metabolic dysfunction in part via increased JNK1/2 pro-inflammatory signaling in L6 cells.

  Antiviral research 20111201

• A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.

  International journal of clinical practice 20111201

• Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.

  AIDS care 20111101

• Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.

  HIV medicine 20111101

• Concurrent atazanavir and voriconazole in a patient with multidrug-resistant HIV and a mycetoma.

  AIDS (London, England) 20111023

• Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults.

  AIDS research and human retroviruses 20111001

• Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy.

  AIDS research and human retroviruses 20111001

• Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.

  HIV medicine 20111001

• Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.

  The Journal of antimicrobial chemotherapy 20111001

• Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with Ritonavir-boosted protease inhibitor monotherapy.

  The Pediatric infectious disease journal 20111001

• Iatrogenic Cushing syndrome after a single intramuscular corticosteroid injection and concomitant protease inhibitor therapy.

  Journal of the American Academy of Dermatology 20111001

• Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.

  AIDS (London, England) 20110924

• [Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].

  Medicina clinica 20110910

• Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.

  The Journal of antimicrobial chemotherapy 20110901

• Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.

  AIDS patient care and STDs 20110901

• Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.

  AIDS (London, England) 20110824

• Medication-based urolithiasis and atazanavir.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20110809

• Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.

  British journal of cancer 20110809

• Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.

  Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 20110801

• Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy.

  Kidney international 20110801

• UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110801

• Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries.

  Journal of acquired immune deficiency syndromes (1999) 20110801

• Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.

  AIDS (London, England) 20110731

• Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

  British journal of clinical pharmacology 20110701

• Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.

  European journal of obstetrics, gynecology, and reproductive biology 20110701

• Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).

  HIV medicine 20110701

• Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

  The Journal of infectious diseases 20110615

• Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.

  Therapeutic drug monitoring 20110601

• Cushing's syndrome due to antiretroviral-budesonide interaction.

  The Annals of pharmacotherapy 20110601

• Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110515

• [Persistence in focus. Atazanavir proves itself anew in long-term therapy].

  MMW Fortschritte der Medizin 20110505

• Gradient RP-HPLC method for the determination of potential impurities in atazanavir sulfate.

  Journal of pharmaceutical and biomedical analysis 20110428

• The use of atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score.

  AIDS (London, England) 20110424

• Atazanavir pharmacokinetics with and without tenofovir during pregnancy.

  Journal of acquired immune deficiency syndromes (1999) 20110415

• Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

  Annals of internal medicine 20110405

• Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20110401

• Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden.

  Scandinavian journal of infectious diseases 20110401

• Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.

  The Journal of infection 20110401

• Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients.

  Journal of pharmacy practice 20110401

• Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.

  Journal of controlled release : official journal of the Controlled Release Society 20110310

• Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.

  Journal of clinical pharmacology 20110301

• Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment.

  Drug metabolism and disposition: the biological fate of chemicals 20110301

• CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism.

  Drug metabolism and disposition: the biological fate of chemicals 20110301

• Detrimental effect of atazanavir plasma concentrations on total serum bilirubin levels in the presence of UGT1A1 polymorphisms.

  Journal of acquired immune deficiency syndromes (1999) 20110301

• Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients.

  Journal of acquired immune deficiency syndromes (1999) 20110301

• FDA notifications. FDA approves new atazanavir labeling.

  AIDS alert 20110301

• Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue.

  Journal of lipid research 20110201

• The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus.

  Arteriosclerosis, thrombosis, and vascular biology 20110201

• Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.

  The Journal of antimicrobial chemotherapy 20110201

• Managing the atazanavir-tacrolimus drug interaction in a renal transplant recipient.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110115

• The toxicogenetics of antiretroviral therapy: the evil inside.

  Current medicinal chemistry 20110101

• HIV-infected adolescents: relationship between atazanavir plasma levels and bilirubin concentrations.

  The Journal of adolescent health : official publication of the Society for Adolescent Medicine 20110101

• Renal disease associated with antiretroviral therapy in the treatment of HIV.

  Nephron. Clinical practice 20110101

• Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.

  Journal of medical economics 20110101

• Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir.

  Antiviral therapy 20110101

• In vitro and in vivo cleavage of HIV-1 RNA by new SOFA-HDV ribozymes and their potential to inhibit viral replication.

  RNA biology 20110101

• The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women.

  Antiviral therapy 20110101

• Interaction between antiretroviral drugs and acenocoumarol.

  Antiviral therapy 20110101

• Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.

  European journal of medical research 20110101

• Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.

  Internal medicine (Tokyo, Japan) 20110101

• Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.

  Antiviral therapy 20110101

• Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.

  HIV clinical trials 20110101

• Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.

  Antiviral therapy 20110101

• Atazanavir in children.

  Prescrire international 20110101

• [Evidence-based therapeutic drug monitoring of atazanavir].

  Therapie 20110101

• Protease inhibitors as preferred initial regimen for antiretroviral-naive HIV patients.

  AIDS reviews 20110101

• Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.

  International journal of nanomedicine 20110101

• Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20101201

• Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.

  Therapeutic drug monitoring 20101201

• Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort.

  AIDS (London, England) 20101127

• Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients.

  HIV medicine 20101101

• Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance.

  Sexually transmitted diseases 20101101

• Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.

  HIV medicine 20101001

• Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20101001

• Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.

  Journal of Korean medical science 20101001

• Recent FDA approvals and changes.

  AIDS patient care and STDs 20101001

• An efficient HPLC method for the quantitative determination of atazanavir in human plasma suitable for bioequivalence and pharmacokinetic studies in healthy human subjects.

  Journal of pharmaceutical and biomedical analysis 20100921

• Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure.

  AIDS (London, England) 20100910

• pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions.

  The Journal of pharmacology and experimental therapeutics 20100901

• Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.

  The Journal of antimicrobial chemotherapy 20100901

• Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.

  AIDS (London, England) 20100824

• Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.

  The Journal of antimicrobial chemotherapy 20100801

• Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.

  AIDS (London, England) 20100717

• Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100701

• Factors predictive of virological failure on atazanavir in 310 HIV-infected patients.

  AIDS (London, England) 20100619

• Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.

  AIDS care 20100601

• Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.

  AIDS (London, England) 20100515

• Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.

  HIV medicine 20100501

• HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.

  Biochimica et biophysica acta 20100501

• Effect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation and differentiation.

  Antiviral research 20100501

• Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal.

  AIDS research and human retroviruses 20100501

• Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.

  AIDS research and human retroviruses 20100501

• [Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus].

  MMW Fortschritte der Medizin 20100429

• The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.

  European journal of clinical pharmacology 20100401

• Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting.

  European journal of clinical pharmacology 20100401

• Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia.

  Archives of toxicology 20100401

• Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.

  AIDS research and human retroviruses 20100401

• Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.

  AIDS (London, England) 20100327

• Trends in uptake of recently approved antiretrovirals within a national healthcare system.

  HIV medicine 20100301

• Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.

  Journal of acquired immune deficiency syndromes (1999) 20100301

• Single-tablet Quad regimen achieves high rate of virologic suppression.

  AIDS patient care and STDs 20100301

• Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.

  Therapeutic drug monitoring 20100201

• Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

  Archives of internal medicine 20100111

• Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.

  HIV medicine 20100101

• Pharmacogenetics of antiretrovirals.

  Antiviral research 20100101

• Factors influencing lopinavir and atazanavir plasma concentration.

  The Journal of antimicrobial chemotherapy 20100101

• Atazanavir-associated choledocholithiasis leading to acute hepatitis in an HIV-infected adult.

  The Annals of pharmacotherapy 20100101

• 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20100101

• Berberine inhibits HIV protease inhibitor-induced inflammatory response by modulating ER stress signaling pathways in murine macrophages.

  PloS one 20100101

• Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.

  PloS one 20100101

• Impact of ritonavir, atazanavir and their combination on the CYP3A4 induction potential of efavirenz in primary human hepatocytes.

  Drug metabolism letters 20100101

• [Adverse reactions of atazanavir, fosamprenavir and tipranavir in 'real life'].

  Therapie 20100101

• HIV protease inhibitors activate the adipocyte renin angiotensin system.

  Antiviral therapy 20100101

• Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.

  Antiviral therapy 20100101

• ICAAC update. Three new drugs in development, plus Isentress with Reyataz.

  Positively aware : the monthly journal of the Test Positive Aware Network 20100101

• Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.

  HIV clinical trials 20100101

• Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir.

  HIV clinical trials 20100101

• Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen.

  Antiviral therapy 20100101

• Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.

  Antiviral therapy 20100101

• Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.

  Antiviral therapy 20100101

• In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.

  Antiviral therapy 20100101

• Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20091101

• Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.

  The Journal of antimicrobial chemotherapy 20091101

• Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients.

  Pharmacotherapy 20091101

• Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.

  Journal of acquired immune deficiency syndromes (1999) 20091101

• Clinical pharmacology, efficacy and safety of atazanavir: a review.

  Expert opinion on drug metabolism & toxicology 20091101

• Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.

  Current HIV research 20091101

• Lithiasis of semicircular canals and parotid glands: unusual stones deposition in atazanavir-treated individuals.

  AIDS (London, England) 20091023

• Atazanavir-related renal insufficiency without concurrent tenofovir.

  Enfermedades infecciosas y microbiologia clinica 20091001

• Response to Crum-Cianflone et al., syphilitic hepatitis among HIV-infected patients.

  International journal of STD & AIDS 20091001

• Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir--the ARTEN Study.

  Journal watch. AIDS clinical care 20091001

• Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor.

  Drug metabolism and disposition: the biological fate of chemicals 20090901

• The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.

  Expert review of anti-infective therapy 20090901

• Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20090801

• Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.

  Pharmacotherapy 20090801

• Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.

  AIDS (London, England) 20090717

• A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.

  The Cochrane database of systematic reviews 20090708

• Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.

  The Journal of antimicrobial chemotherapy 20090701

• HIV protease inhibitors: recent clinical trials and recommendations on use.

  Expert opinion on pharmacotherapy 20090701

• Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy.

  Journal of clinical epidemiology 20090601

• Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.

  Infection 20090601

• Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.

  The Journal of antimicrobial chemotherapy 20090601

• Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir.

  Journal of acquired immune deficiency syndromes (1999) 20090601

• Efficacy and safety of atazanavir in patients with end-stage liver disease.

  Infection 20090601

• Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.

  Infection 20090601

• Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.

  Prescrire international 20090601

• Atazanavir: a review of its use in the management of HIV-1 infection.

  Drugs 20090529

• Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.

  Proteins 20090515

• Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cells.

  Vaccine 20090514

• Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.

  HIV medicine 20090501

• Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090501

• Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

  Journal of acquired immune deficiency syndromes (1999) 20090501

• Provider prescribing of 4 antiretroviral agents after implementation of drug use guidelines in the Department of Veterans Affairs.

  Journal of managed care pharmacy : JMCP 20090501

• Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.

  Current drug safety 20090501

• [Medication change due to side effects or possible long-term complications. Side effect management with vision].

  MMW Fortschritte der Medizin 20090430

• A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults.

  Clinical pharmacology and therapeutics 20090401

• HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone.

  Experimental biology and medicine (Maywood, N.J.) 20090401

• Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.

  The AIDS reader 20090401

• Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.

  The Journal of infectious diseases 20090315

• Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial.

  Heart (British Cardiac Society) 20090301

• Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line.

  Journal of neuroscience research 20090301

• Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090301

• Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20090301

• Protease inhibitor levels in hair strongly predict virologic response to treatment.

  AIDS (London, England) 20090220

• Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.

  Advances in therapy 20090201

• [Atazanavir-induced nephrolithiasis].

  Enfermedades infecciosas y microbiologia clinica 20090201

• HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.

  AIDS (London, England) 20090128

• Low atazanavir concentrations in cerebrospinal fluid.

  AIDS (London, England) 20090102

• Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effects.

  Biostatistics (Oxford, England) 20090101

• Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.

  Clinical chemistry 20090101

• Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.

  TreatmentUpdate 20090101

• Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.

  HIV clinical trials 20090101

• Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy.

  HIV clinical trials 20090101

• Baseline lipid levels rather than the presence of reported body shape changes determine the degree of improvement in lipid levels after switching to atazanavir.

  HIV clinical trials 20090101

• Novel methodology for antiretroviral quantitation in the female genital tract.

  HIV clinical trials 20090101

• Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.

  HIV clinical trials 20090101

• Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.

  BMC infectious diseases 20090101

• Comparison of 3-drug versus 4-drug and PI versus non-PI combinations as initial HAART: experience from 1998 to 2007.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.

  HIV clinical trials 20090101

• P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir.

  Antiviral therapy 20090101

• The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe.

  Clinical pharmacology and therapeutics 20081201

• Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir.

  European journal of clinical pharmacology 20081201

• A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease.

  The Journal of antimicrobial chemotherapy 20081201

• Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.

  Therapeutic drug monitoring 20081201

• Atazanavir: its role in HIV treatment.

  Expert review of anti-infective therapy 20081201

• CASTLE analysis finds no benefit for once daily dosing.

  Project Inform perspective 20081201

• 96-week data from CASTLE study presented.

  Project Inform perspective 20081201

• Report from the 2008 joint ICAAC/IDSA meeting. Darunavir and atazanavir: 96-week data from ARTEMIS and CASTLE.

  AIDS clinical care 20081201

• [Introduction. Usefulness of atazanavir in the treatment of patients infected by human immunodeficiency virus].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Pharmacology, pharmacokinetic features and interactions of atazanavir].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Efficacy of atazanavir in treatment-naive patients].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Efficacy of atazanavir in simplification regimens].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Efficacy of atazanavir in rescue therapy].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Viral resistance and genetic barrier of atazanavir].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Lipid profile of atazanavir].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Adverse effects of atazanavir].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Utility of atazanavir in special populations].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Clinical utility of atazanavir].

  Enfermedades infecciosas y microbiologia clinica 20081201

• Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin.

  AIDS (London, England) 20081130

• Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient.

  AIDS (London, England) 20081112

• Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20081101

• Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression.

  Current HIV research 20081101

• 96-week CASTLE data show similar efficacy results.

  AIDS patient care and STDs 20081101

• FDA notifications. Alternative dosing regimen for atazanavir is approved.

  AIDS alert 20081101

• Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line.

  Pharmaceutical research 20081001

• Acute renal failure due to bilateral ureteral stone impaction in an HIV-positive patient.

  Urological research 20081001

• Maraviroc: in vitro assessment of drug-drug interaction potential.

  British journal of clinical pharmacology 20081001

• Low-dose, once-daily atazanavir/ritonavir (200/100): an effective treatment for HIV-infected patients in Thailand.

  Journal of acquired immune deficiency syndromes (1999) 20081001

• FDA notifications. Updates made to Reyataz package insert.

  AIDS alert 20081001

• Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.

  Clinical therapeutics 20081001

• Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation.

  Virology 20080915

• The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.

  The Journal of antimicrobial chemotherapy 20080901

• Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier.

  AIDS research and human retroviruses 20080901

• Labeling changes for Reyataz.

  AIDS patient care and STDs 20080901

• CASTLE data show no gender differences.

  AIDS patient care and STDs 20080901

• Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs.

  Current HIV research 20080901

• A king in the CASTLE? Optimum initial HIV protease inhibitor.

  Lancet (London, England) 20080823

• Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

  Lancet (London, England) 20080823

• Electrocardiographic changes in HIV-infected, drug experienced patients treated with atazanavir.

  AIDS (London, England) 20080820

• No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080815

• CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.

  European journal of clinical pharmacology 20080801

• The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20080801

• Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080801

• Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.

  International journal of STD & AIDS 20080801

• Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.

  Journal of Korean medical science 20080801

• Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes.

  AIDS (London, England) 20080711

• HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20080701

• Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.

  Archives of toxicology 20080701

• Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080701

• Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection.

  Journal of chromatographic science 20080701

• Quality control of protease inhibitors.

  Journal of pharmaceutical sciences 20080601

• The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients.

  Journal of acquired immune deficiency syndromes (1999) 20080601

• Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.

  AIDS research and human retroviruses 20080601

• Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats.

  Biological & pharmaceutical bulletin 20080601

• Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.

  Journal of cardiovascular pharmacology 20080601

• Pharmacogenomics of antiretrovirals.

  Recent patents on anti-infective drug discovery 20080601

• Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.

  Journal of clinical pharmacology 20080501

• [Acute renal failure associated with the use of tenofovir combined with atazanavir in patients with HIV infection].

  Enfermedades infecciosas y microbiologia clinica 20080501

• FDA notifications. Atazanavir capsule label is updated for pediatric patients.

  AIDS alert 20080501

• [Metabolic changes in PI-based HAART. Change to atazanavir: continued effectiveness with improved lipid profile].

  MMW Fortschritte der Medizin 20080428

• Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.

  The Journal of antimicrobial chemotherapy 20080401

• Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

  British journal of clinical pharmacology 20080401

• Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.

  HIV medicine 20080401

• New pediatric dosing recommendations for atazanavir.

  AIDS patient care and STDs 20080401

• Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080401

• Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.

  HIV medicine 20080301

• Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.

  Pharmacotherapy 20080301

• CASTLE study showed similar efficacy.

  AIDS patient care and STDs 20080301

• Revised package insert for atazanavir.

  AIDS clinical care 20080301

• FDA notifications. FDA tentatively approves generic atazanavir.

  AIDS alert 20080301

• FDA notifications. Revised atazanavir package insert.

  AIDS alert 20080301

• Anti-HIV agents. The Castle study: lopinavir vs. atazanavir.

  TreatmentUpdate 20080301

• Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.

  Journal of acquired immune deficiency syndromes (1999) 20080201

• Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20080201

• Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.

  Antimicrobial agents and chemotherapy 20080201

• Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.

  Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20080201

• Progression of Kaposi sarcoma associated with iatrogenic Cushing syndrome in a person with HIV/AIDS.

  The AIDS reader 20080201

• Urolithiasis under atazanavir boosted and tenofovir therapy: a case report.

  Journal of chemotherapy (Florence, Italy) 20080201

• Atazanavir/ritonavir: a review of its use in HIV therapy.

  Drugs of today (Barcelona, Spain : 1998) 20080201

• Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.

  The Journal of antimicrobial chemotherapy 20080101

• Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.

  AIDS patient care and STDs 20080101

• Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20080101

• Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.

  Journal of neurovirology 20080101

• Case presentation: nephrolithiasis in a patient treated with atazanavir.

  The Journal of the Association of Nurses in AIDS Care : JANAC 20080101

• Atazanavir in patients with persistent viral replication despite HAART: results from the French prospective NADIS cohort.

  HIV clinical trials 20080101

• Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.

  HIV clinical trials 20080101

• Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.

  HIV clinical trials 20080101

• Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.

  Antiviral therapy 20080101

• XVII International AIDS Conference--Mexico City, August 3-8, 2008. Metabolic complications and hepatitis co-infection. News from the International AIDS Conference.

  Positively aware : the monthly journal of the Test Positive Aware Network 20080101

• [Simplification of HAART scheme--treatment optimization].

  Terapevticheskii arkhiv 20080101

• Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.

  HIV clinical trials 20080101

• Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

  Drug and alcohol dependence 20071201

• Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.

  AIDS (London, England) 20071130

• HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.

  Cancer research 20071115

• Atazanavir crystal nephropathy.

  AIDS (London, England) 20071112

• Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity.

  AIDS (London, England) 20071112

• HIV protease inhibitors increase TNF-alpha and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR.

  Atherosclerosis 20071101

• Urolithiasis in HIV-positive patients treated with atazanavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20071015

• Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.

  European journal of clinical pharmacology 20071001

• Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.

  The Journal of antimicrobial chemotherapy 20071001

• Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.

  HIV medicine 20071001

• Treatment of an atazanivir associated grade 4 hyperbilirubinaemia with efavirenz.

  Gut 20071001

• Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.

  Therapeutic drug monitoring 20071001

• Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

  Therapeutic drug monitoring 20071001

• Reyataz monotherapy study stopped.

  Project Inform perspective 20071001

• Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.

  AIDS (London, England) 20070912

• Efavirenz urolithiasis.

  AIDS (London, England) 20070912

• Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.

  Antimicrobial agents and chemotherapy 20070901

• Atazanavir-associated menorrhagia.

  International journal of STD & AIDS 20070901

• Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy.

  Journal of acquired immune deficiency syndromes (1999) 20070901

• Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.

  AIDS (London, England) 20070820

• Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.

  AIDS (London, England) 20070731

• [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].

  Medicina clinica 20070714

• Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein.

  The Journal of antimicrobial chemotherapy 20070701

• The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial.

  AIDS (London, England) 20070619

• Alopecia associated with ritonavir-boosted atazanavir therapy.

  AIDS (London, England) 20070619

• Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20070601

• Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies.

  Virchows Archiv : an international journal of pathology 20070601

• The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070601

• Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070601

• Cushing syndrome and severe adrenal suppression caused by fluticasone and protease inhibitor combination in an HIV-infected adolescent.

  AIDS patient care and STDs 20070601

• Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.

  AIDS (London, England) 20070531

• Atazanavir-containing renal calculi in an HIV-infected patient.

  AIDS (London, England) 20070511

• Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.

  Journal of pharmaceutical and biomedical analysis 20070509

• Atazanavir in plasma-exchange treatment.

  AIDS (London, England) 20070423

• Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

  Lancet (London, England) 20070414

• An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401

• Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.

  Journal of acquired immune deficiency syndromes (1999) 20070401

• Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.

  The Journal of infectious diseases 20070401

• Atazanavir: simplicity and convenience in different scenarios.

  Expert opinion on pharmacotherapy 20070401

• Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects.

  European journal of endocrinology 20070401

• Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system.

  Biological & pharmaceutical bulletin 20070401

• Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review.

  The new microbiologica 20070401

• Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients.

  Statistics in medicine 20070315

• Prolonged QT interval and torsades de pointes associated with atazanavir therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070315

• High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.

  Journal of pharmaceutical and biomedical analysis 20070312

• Modification of tandem mass spectrometric method to permit simultaneous quantification of 17 anti-HIV drugs which include atazanavir and tipranavir.

  Clinica chimica acta; international journal of clinical chemistry 20070301

• Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.

  Pharmacogenomics 20070301

• Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.

  HIV medicine 20070301

• Development and validation of a preclinical food effect model.

  Journal of pharmaceutical sciences 20070201

• Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers.

  Journal of clinical pharmacology 20070201

• Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.

  Therapeutic drug monitoring 20070201

• Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.

  AIDS (London, England) 20070102

• Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070101

• Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.

  Clinical drug investigation 20070101

• A comparison of different protease inhibitors on coronary heart disease risk.

  Connecticut medicine 20070101

• Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.

  Antiviral therapy 20070101

• Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.

  Antiviral therapy 20070101

• Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.

  Drugs in R&D 20070101

• Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.

  Journal of the American Board of Family Medicine : JABFM 20070101

• Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.

  Antiviral therapy 20070101

• Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.

  Clinical drug investigation 20070101

• Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir.

  The American journal on addictions 20070101

• Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.

  Journal of acquired immune deficiency syndromes (1999) 20061215

• Meeting report. Report from ICAAC.

  AIDS clinical care 20061201

• Atazanavir urolithiasis.

  The New England journal of medicine 20061116

• Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20061101

• Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.

  Hepatology (Baltimore, Md.) 20061101

• Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.

  AIDS patient care and STDs 20061101

• New atazanavir capsule approved.

  AIDS patient care and STDs 20061101

• Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring.

  Journal of molecular biology 20061027

• Therapeutic ritonavir-boosted atazanavir plasma concentration and concurrent omeprazole use.

  AIDS (London, England) 20061024

• Atazanavir urinary stones in an HIV-infected patient.

  AIDS (London, England) 20061024

• Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection.

  Journal of pharmaceutical and biomedical analysis 20061011

• Response to 'Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?' by Hill.

  AIDS (London, England) 20061003

• Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.

  The Annals of pharmacotherapy 20061001

• Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.

  AIDS (London, England) 20060911

• Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.

  The Pediatric infectious disease journal 20060901

• Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II.

  Journal of psychiatric practice 20060901

• Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

  JAMA 20060816

• Further information on the administration of h2-receptor antagonists with atazanavir.

  Journal of acquired immune deficiency syndromes (1999) 20060801

• An update and review of antiretroviral therapy.

  Pharmacotherapy 20060801

• Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring.

  Therapeutic drug monitoring 20060801

• Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.

  AIDS research and human retroviruses 20060801

• Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.

  European journal of clinical pharmacology 20060701

• A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients.

  HIV medicine 20060701

• [Acute tubulointerstitial nephritis in HIV infection].

  Praxis 20060607

• Can boosted atazanavir induce hyperlipotrophy?

  The Journal of infection 20060601

• Rescue therapy with once-daily atazanavir-based regimens for antiretroviral-experienced HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20060601

• Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.

  AIDS (London, England) 20060512

• Skin rash associated with atazanavir: report of three cases.

  AIDS (London, England) 20060512

• Unexpected improvement of sexual dysfunction during atazanavir therapy.

  AIDS (London, England) 20060512

• Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.

  Biochemistry 20060502

• Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir.

  The Journal of antimicrobial chemotherapy 20060501

• Ritonavir-boosted atazanavir may be efficacious in HIV-infected patients concurrently receiving omeprazole.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060501

• External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients.

  Journal of acquired immune deficiency syndromes (1999) 20060501

• A single centre cohort experience with a new once daily antiretroviral drug.

  Postgraduate medical journal 20060501

• Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy.

  AIDS (London, England) 20060424

• Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.

  AIDS (London, England) 20060424

• Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.

  AIDS (London, England) 20060404

• Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection.

  Pharmacotherapy 20060401

• The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20060401

• Report from the 13th retrovirus conference. Extending the role of atazanavir.

  AIDS clinical care 20060401

• 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.

  AIDS (London, England) 20060321

• Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir.

  AIDS (London, England) 20060321

• Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.

  Pharmacotherapy 20060301

• Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir.

  Journal of acquired immune deficiency syndromes (1999) 20060301

• Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?

  Journal of acquired immune deficiency syndromes (1999) 20060301

• Early clinical experience with atazanavir in treatment-experienced patients.

  Sexual health 20060301

• A monolithic-phase based on-line extraction approach for determination of pharmaceutical components in human plasma by HPLC-MS/MS and a comparison with liquid-liquid extraction.

  Journal of pharmaceutical and biomedical analysis 20060224

• Some PIs have greater impact than others on heart disease. Patients on atazanavir had less heart problems.

  AIDS alert 20060201

• Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060115

• Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060115

• Human placental transfer of atazanavir: a case report.

  AIDS (London, England) 20060109

• Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.

  AIDS (London, England) 20060102

• A case of transient hyperphosphatasemia of infancy and early childhood in an HIV-positive adult possibly related to atazanavir.

  AIDS (London, England) 20060102

• Liquid chromatographic assay for the protease inhibitor atazanavir in plasma.

  Biomedical chromatography : BMC 20060101

• Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20060101

• Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

  Antiviral therapy 20060101

• Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations.

  HIV clinical trials 20060101

• Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.

  Antiviral therapy 20060101

• Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).

  Antiviral therapy 20060101

• Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.

  HIV clinical trials 20060101

• Drug interactions. Is atazanavir best when boosted with ritonavir?

  TreatmentUpdate 20060101

• Drug interactions. Atazanavir and acid-reducing agents.

  TreatmentUpdate 20060101

• Drug interactions. Brecanavir--a new protease inhibitor.

  TreatmentUpdate 20060101

• Drug interactions. Kaletra and atazanavir.

  TreatmentUpdate 20060101

• Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.

  Journal of acquired immune deficiency syndromes (1999) 20051201

• Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes.

  The AIDS reader 20051201

• Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?

  AIDS (London, England) 20051118

• Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir.

  AIDS (London, England) 20051104

• In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.

  Drug metabolism and disposition: the biological fate of chemicals 20051101

• Rash in an HIV-positive patient.

  HIV medicine 20051101

• Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction.

  AIDS (London, England) 20051014

• Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy.

  AIDS (London, England) 20051014

• PI monotherapy effective as maintenance.

  AIDS patient care and STDs 20051001

• Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.

  Current medical research and opinion 20051001

• Determination of atazanavir in human plasma using solid-phase extraction and high-performance liquid chromatography.

  Journal of pharmaceutical and biomedical analysis 20050915

• Unexpected improvement of sexual dysfunction during atazanavir therapy.

  AIDS (London, England) 20050902

• Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic.

  British journal of clinical pharmacology 20050901

• Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity.

  Journal of acquired immune deficiency syndromes (1999) 20050815

• Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.

  The Journal of antimicrobial chemotherapy 20050801

• Co-administration of atazanavir with proton-pump inhibitors and H2 blockers.

  Journal of acquired immune deficiency syndromes (1999) 20050801

• Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.

  European journal of clinical pharmacology 20050801

• Review of atazanavir: a novel HIV protease inhibitor.

  Expert opinion on pharmacotherapy 20050801

• The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with lipodystrophy.

  HIV medicine 20050701

• Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.

  Drug metabolism and disposition: the biological fate of chemicals 20050601

• Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia.

  Journal of acquired immune deficiency syndromes (1999) 20050601

• Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasma.

  Therapeutic drug monitoring 20050601

• Lipodystrophy is associated with a low rate of treatment failure in HIV-positive patients switched to atazanavir.

  Journal of acquired immune deficiency syndromes (1999) 20050501

• Impact of acid-suppressive therapy on virologic response to atazanavir-based regimens in antiretroviral-experienced patients: a case series.

  Journal of acquired immune deficiency syndromes (1999) 20050501

• [Current status of HIV protease inhibitors].

  Yao xue xue bao = Acta pharmaceutica Sinica 20050501

• Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

  AIDS (London, England) 20050429

• [New data on atazanavir/r]].

  MMW Fortschritte der Medizin 20050425

• Atazanavir: a novel inhibitor of HIV-protease in haemodialysis.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050401

• Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.

  Therapeutic drug monitoring 20050401

• FDA notifications. BMS issues letter about omeprazole.

  AIDS alert 20050401

• Atazanavir affects saquinavir.

  AIDS patient care and STDs 20050401

• Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.

  The new microbiologica 20050401

• Lack of interaction between atazanavir and lansoprazole.

  AIDS (London, England) 20050324

• Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.

  The American journal of cardiology 20050301

• Atazanavir not to be used with proton pump inhibitors.

  AIDS patient care and STDs 20050201

• Avoid PPIs with atazanavir.

  AIDS clinical care 20050201

• Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

  AIDS (London, England) 20050128

• Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety.

  European journal of medical research 20050128

• Boosted Reyataz comparable to Kaletra.

  AIDS patient care and STDs 20050101

• Atazanavir: the advent of a new generation of more convenient protease inhibitors.

  HIV clinical trials 20050101

• Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

  Clinical pharmacokinetics 20050101

• Atazanavir: a review of its use in the management of HIV infection.

  Drugs 20050101

• Anti-HIV agents. Kaletra + atazanavir.

  TreatmentUpdate 20050101

• Anti-HIV agents. Atazanavir vs. Kaletra.

  TreatmentUpdate 20050101

• Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041225

• Atazanavir for the treatment of human immunodeficiency virus infection.

  Pharmacotherapy 20041201

• Reyataz may cause EKG abnormality.

  AIDS patient care and STDs 20041201

• The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.

  AIDS (London, England) 20041105

• Acute interstitial nephritis associated with atazanavir, a new protease inhibitor.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20041101

• Atazanavir: A novel once-daily protease inhibitor.

  Drugs of today (Barcelona, Spain : 1998) 20041101

• Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041015

• Pseudoaneurysm of the femoral artery in a HIV-infected man.

  European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20041001

• Atazanavir.

  The Annals of pharmacotherapy 20041001

• Recent changes to FDA-approved labeling.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040901

• New dosing regimen for atazanavir.

  AIDS patient care and STDs 20040901

• Management of HIV-infected patients with multidrug-resistant virus.

  Current HIV/AIDS reports 20040901

• Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

  Journal of acquired immune deficiency syndromes (1999) 20040815

• Acute hepatic cytolysis in an HIV-infected patient taking atazanavir.

  AIDS (London, England) 20040723

• Atazanavir: a new protease inhibitor to treat HIV infection.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040701

• Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.

  AIDS (London, England) 20040618

• Atazanavir: new option for treatment of HIV infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040601

• Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.

  Journal of acquired immune deficiency syndromes (1999) 20040601

• [Recent progress in anti-HIM-1 research].

  Uirusu 20040601

• Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040525

• Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.

  The Journal of infectious diseases 20040515

• [New treatment options for HIV-infected patients].

  Deutsche medizinische Wochenschrift (1946) 20040507

• Does atazanavir cause lipodystrophy?

  Journal of HIV therapy 20040501

• [Simplified HIV therapy. Atazanavir: the first protease inhibitor with once daily administration].

  MMW Fortschritte der Medizin 20040426

• [Long-term tolerance. Favorable lipid profile--favorable effect on development of lipodystrophy?].

  MMW Fortschritte der Medizin 20040426

• [Interview with Professor Jürgen Rockstroh, director of the Bonn University Clinic. Atazanavir in general practice].

  MMW Fortschritte der Medizin 20040426

• [Good experiences with saquinavir. Double boosting of protease inhibitors gains significance].

  MMW Fortschritte der Medizin 20040426

• [Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].

  MMW Fortschritte der Medizin 20040426

• Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir.

  AIDS (London, England) 20040409

• Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread) -- and warning on Viagra, Cialis, and Levitra.

  AIDS treatment news 20040326

• Optimizing dosing strategies for the combination of atazanavir plus saquinavir.

  AIDS (London, England) 20040305

• Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040301

• Initial therapy for human immunodeficiency virus: broadening the options.

  HIV clinical trials 20040101

• Boosted Reyataz: 48-week results.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20040101

• Peptidomimetic inhibitors of HIV protease.

  Current topics in medicinal chemistry 20040101

• Predictors of virological response to atazanavir in protease inhibitor-experienced patients.

  HIV clinical trials 20040101

• Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20040101

• Strategies for overcoming resistance in HIV-1 infected patients receiving HAART.

  AIDS reviews 20040101

• Warning: do not combine Reyataz and Prilosec.

  AIDS treatment news 20040101

• Anti-HIV agents. Atazanavir and saquinavir.

  TreatmentUpdate 20040101

• [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].

  MMW Fortschritte der Medizin 20031211

• Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.

  AIDS (London, England) 20031205

• Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients.

  AIDS (London, England) 20031205

• The continuing evolution of HIV therapy.

  The AIDS reader 20031201

• Atazanavir (Reyataz) and emtricitabine (Emtriva) for HIV infection.

  The Medical letter on drugs and therapeutics 20031110

• Atazanavir sulphate.

  Nature reviews. Drug discovery 20031101

• Liquid chromatography-tandem mass spectrometric quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human peripheral blood mononuclear cells (PBMC): practical approaches to PBMC preparation and PBMC assay design for high-throughput analysis.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20031005

• Releasing the true power of protease inhibitors.

  International journal of STD & AIDS 20031001

• Atazanavir (Reyataz).

  Project Inform perspective 20031001

• Atazanavir: improving the HIV protease inhibitor class.

  Expert review of anti-infective therapy 20031001

• [Atazanavir--first protease inhibitor for one dose administration].

  Deutsche medizinische Wochenschrift (1946) 20030926

• Boosted PIs: competition hots up.

  The AIDS reader 20030901

• Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients.

  AIDS clinical care 20030901

• BMS issues PK notice regarding ATV + TDF.

  IAPAC monthly 20030901

• FDA notifications. Reyataz is approved for HIV treatment.

  AIDS alert 20030901

• [New protease inhibitor against HIV. Viral load decreases--without lipid increase].

  MMW Fortschritte der Medizin 20030821

• HIV therapeutics, continued: another HIV protease inhibitor approved.

  The AIDS reader 20030801

• Atazanavir: clinical use.

  The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20030701

• Drug profile: atazanavir (Reyataz, ATV).

  The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20030701

• New protease inhibitor atazanavir (Reyataz) approved.

  AIDS treatment news 20030627

• Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.

  AIDS (London, England) 20030613

• Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20030601

• Reviving protease inhibitors: new data and more options.

  Journal of acquired immune deficiency syndromes (1999) 20030601

• Atazanavir gets FDA Advisory Committee's thumbs-up.

  IAPAC monthly 20030601

• Atazanavir background documents available.

  AIDS treatment news 20030530

• Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030525

• Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples.

  AIDS (London, England) 20030523

• [Highly effective drug without modifying the lipid profile. Atazanavir, the protease inhibitor for 'once daily' administration].

  MMW Fortschritte der Medizin 20030428

• ['Once daily' drugs simplify therapy. Rp. HAART once daily].

  MMW Fortschritte der Medizin 20030428

• [Highly effective and tolerable protease inhibitor. New trump card against HIV].

  MMW Fortschritte der Medizin 20030116

• Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.

  Journal of acquired immune deficiency syndromes (1999) 20030101

• Anti-HIV drug updates--three drugs on the near horizon.

  Project Inform perspective 20030101

• Atazanavir.

  Drugs 20030101

• First once-daily protease inhibitor.

  FDA consumer 20030101

• Three new drugs approved by FDA.

  Survival news (Atlanta, Ga.) 20030101

• Anti-HIV agents. Atazanavir as a booster for protease inhibitors.

  TreatmentUpdate 20030101

• Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Atazanavir--booster of the future?

  TreatmentUpdate 20030101

• [Simple, safe and effective. New protease inhibitor means progress].

  MMW Fortschritte der Medizin 20021205

• Atazanavir: a novel HIV-1 protease inhibitor.

  Expert opinion on investigational drugs 20020901

• Promising new agents on the horizon.

  AIDS clinical care 20020301

• [Progress toward a once daily regimen. (HA)ART--the art of antiretroviral therapy].

  MMW Fortschritte der Medizin 20010402

• Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable.

  The Journal of infectious diseases 20010401

• BMS-232632 (Novartis/Bristol-Myers Squibb).

  Current opinion in investigational drugs (London, England : 2000) 20010301

• New antiretroviral agents.

  The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20010301

• A new protease inhibitor from Bristol-Myers Squibb.

  TreatmentUpdate 20010101

• In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.

  Antimicrobial agents and chemotherapy 20000901

• BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.

  Antimicrobial agents and chemotherapy 20000801